Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariusz Bidzinski

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
JCI Insight|June 2, 2017
Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomasJoanna Przybyl, Magdalena Kowalewska, Anna Quattrone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancerNicoletta Colombo, Elzbieta Kutarska, Meletios Dimopoulos, et al.
Journal for Immunotherapy of Cancer|January 8, 2025
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a studyPeter Hillemanns, Michal Zikan, Frédéric Forget, et al.
Clinical and Translational Medicine|January 10, 2026
Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumoursRachel N Grisham, Elizabeth Hopp, Kathryn Pennington, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 26, 2017
European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar CancerMaaike H M Oonk, François Planchamp, Peter Baldwin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancerBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2013
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA studyPaul Sabbatini, Philipp Harter, Giovanni Scambia, et al.
Lancet (London, England)|April 13, 2026
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 studyNicoletta Colombo, Emese Zsiros, Gabriella Parma, et al.
Nature Genetics|March 29, 2013
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancerStig E Bojesen, Karen A Pooley, Sharon E Johnatty, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
JCI Insight|June 2, 2017
Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomasJoanna Przybyl, Magdalena Kowalewska, Anna Quattrone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancerNicoletta Colombo, Elzbieta Kutarska, Meletios Dimopoulos, et al.
Journal for Immunotherapy of Cancer|January 8, 2025
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a studyPeter Hillemanns, Michal Zikan, Frédéric Forget, et al.
Clinical and Translational Medicine|January 10, 2026
Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumoursRachel N Grisham, Elizabeth Hopp, Kathryn Pennington, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 26, 2017
European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar CancerMaaike H M Oonk, François Planchamp, Peter Baldwin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancerBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2013
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA studyPaul Sabbatini, Philipp Harter, Giovanni Scambia, et al.
Lancet (London, England)|April 13, 2026
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 studyNicoletta Colombo, Emese Zsiros, Gabriella Parma, et al.
Nature Genetics|March 29, 2013
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancerStig E Bojesen, Karen A Pooley, Sharon E Johnatty, et al.
Pageof 5